United States-based Merck's Keytruda (pembrolizumab) in combination with pemetrexed (Alimta) plus platinum chemotherapy has improved overall survival and progression-free survival of a certain type of lung cancer patients in a phase three trial, it was reported yesterday.
Both overall survival and progression-free survival were defined to be the dual primary endpoints of the pivotal late-stage trial named KEYNOTE-189.
The trial evaluated the combination of Keytruda, Lilly's pemetrexed and platinum chemotherapy made up of cisplatin or carboplatin as a first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC). The Keytruda regimen was assessed in comparison to pemetrexed and cisplatin or carboplatin alone in 614 NSCLC patients, regardless of PD-L1 expression. According to Merck, the safety profile of Keytruda in the combination was on par with previous observations.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer